Multiple Myeloma Coverage From Every Angle
Advertisement
Advertisement

Noopur S. Raje, MD, and Kenneth C. Anderson, MD, on Myeloma Bone Disease: Denosumab and Zoledronic Acid

Posted: Wednesday, September 20, 2017

Kenneth C. Anderson, MD, of Dana-Farber Cancer Institute, and Noopur S. Raje, MD, of the Massachusetts General Hospital Cancer Center, discuss the impact of denosumab compared with zoledronic acid on renal function in the treatment of myeloma bone disease.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.